See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin, a selective inhibitor of oncogenic transcription, has been associated with certain side effects that can lead to treatment interruptions [1]. According to the available information, the specific side effects that may result in treatment interruptions include:

1. Myelosuppression: Lurbinectedin can cause neutropenia, thrombocytopenia, and anemia, which may require dose adjustments or interruptions [1][2].
2. Gastrointestinal toxicities: Nausea, vomiting, and diarrhea are common side effects of lurbinectedin. Severe cases may necessitate treatment interruptions [1][2].
3. Hepatotoxicity: Elevations in liver enzymes have been observed in some patients, potentially leading to treatment interruptions [1].

It is essential to monitor patients closely during lurbinectedin treatment and manage side effects promptly to minimize the need for treatment interruptions [1].

Sources:

1. [Lurbinectedin in Adult Patients With Relapsed Small Cell Lung Cancer (SCLC)](https://clinicaltrials.gov/ct2/show/NCT02454972)
2. [Lurbinectedin in the Treatment of Relapsed Small Cell Lung Cancer (SCLC)](https://www.drugpatentwatch.com/drug/lurbinectedin)